Articles
DOI DOI: 10.62441/actainnovations.vi.3132

MINIMAL CHANGE DISEASE AS RARE RENAL MANIFESTATION OF PSORIASIS IN A YOUNG ADULT: A CASE REPORT

Abstract

Minimal Change Disease (MCD) is the main cause of primary nephrotic syndrome in about 90% of children, but it's very rare in adults, where it accounts for only 10% to 15% of cases. MCD is marked by symptoms like excessive protein in the urine, low levels of albumin in the blood, swelling, and high cholesterol [1,2]. It can be primary, meaning it starts on its own without a known cause, or it can be secondary, meaning it's caused by other conditions like certain medications such as Non-steroidal Anti-inflammatory Drugs (NSAIDs), cancers, infections, or other diseases affecting the kidneys or the body. These secondary causes make up up to 15% of MCD cases in adults [1]. Therefore, it's important to take a detailed medical history when diagnosing MCD in adults because treatment depends on finding the underlying cause.

How to Cite

Warapsari, R., Hertanto, D. M., Irwanadi, C., Rahaju, A. S., Pramudya, D., & Santoso, D. (2026). MINIMAL CHANGE DISEASE AS RARE RENAL MANIFESTATION OF PSORIASIS IN A YOUNG ADULT: A CASE REPORT. ACTA INNOVATIONS, 983–988. https://doi.org/10.62441/actainnovations.vi.3132

References

  1. 1. Nicholas PD, Garrahy I. Adult minimal change disease with acute kidney injury: a case report and literature review. J Community Hosp Intern Med Perspect. 2019;9(6):507–10.
  2. 2. Saleem MA, Kobayashi Y. Cell biology and genetics of minimal change disease. F1000Res. 2016;5:F1000.
  3. 3. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–912.
  4. 4. Zadrazil J, Tichy T, Horak P, et al. IgA nephropathy associated with psoriasis vulgaris: A contribution to the entity of "psoriatic nephropathy". J Nephrol. 2006;19(3):382–6.
  5. 5. Debnath P, Okoye CC, Zia A, Chaudhury SR, Frolova E. Minimal Change Disease as a Sequela of Psoriasis in an Adult [Abstract]. J Am Soc Nephrol. 2021;32(10S):522.
  6. 6. Lok KH, Hung HG, Yip WM, Li KK, Li KF, Szeto ML. Fulminant ulcerative colitis associated with steroid-resistant minimal change disease and psoriasis: A case report. World J Gastroenterol. 2007;13(28):3889–91.
  7. 7. Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018;27(2):115–23.
  8. 8. Al-Oudah GA. Psoriatic-nephropathy; an under-noticed disease. J Nephropharmacol. 2025;14:e12752.
  9. 9. Grandinetti V, Baraldi O, Comai G, Corradetti V, Aiello V, Bini C, et al. Renal dysfunction in psoriatic patients. G Ital Nefrol. 2020;37(5):2020-vol1.
  10. 10. Ren F, Zhan X, Martens G, Lee J, Center D, Adamson A, et al. Psoriasis-like inflammation induced renal dysfunction through the TLR/NF-κB signal pathway. Biomed Res Int. 2020;2020:3535264.
  11. 11. Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G. Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol. 2015;54(4):478–81.
  12. 12. Akoglu H, Dede F, Akoglu G, Gonul II, Odabas AR. Membranoproliferative glomerulonephritis associated with psoriasis vulgaris. Ren Fail. 2009;31:858–61.
  13. 13. Qi C, Chen L, Shen P, Li X, Pan X, Xu J, Xie J. Renal biopsy findings in psoriasis patients with renal involvement: a descriptive clinicopathologic study. BMC Nephrol. 2026;27:114.
  14. 14. Grimbert P, Audard V, Remy P, Lang P, Sahali D. Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant. 2003;18(2):245–8.
  15. 15. Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332–45.
  16. 16. KDIGO Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–276.
  17. 17. Waldman M, Crew RJ, Valeri A, Appel J, Sterman L, Chois MH, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–53.
  18. 18. Glassock RJ. Secondary minimal change disease. Nephrol Dial Transplant. 2003;18(suppl 6):vi52–8.
  19. 19. Ranganathan S. Pathology of podocytopathies causing nephrotic syndrome in children. Front Pediatr. 2016;4:32.
  20. 20. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities. J Am Acad Dermatol. 2019;81(2):557–77.
  21. 21. Nast A, Gisondi P, Ormerod AD, Spuls PI, Augustin M, de Jong EM, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94.
  22. 22. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273–9.
  23. 23. Araya CE, Wasserfall CH, Brusko TM, Mu W, Segal MS, Johnson RJ, et al. A novel immune-endocrine axis in idiopathic nephrotic syndrome? Pediatric Nephrology. 2005;20(11):1538–44.
  24. 24. Shimoyama H, Nakajima M, Naka H, Maruhashi Y, Akazawa H, Ueda T, et al. Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 2004;19(10):1115–21.
  25. 25. Van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci. 2004;107(2):125–36.
  26. 26. Shimoyama H. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80(3 Pt 2):S40–5.